Overview
flowchart TD
therapeutics["therapeutics"] -->|"protects against"| age_related_cognitive_decline["age-related cognitive decline"]
therapeutics["therapeutics"] -->|"inhibits"| neuroinflammation["neuroinflammation"]
Therapeutics["Therapeutics"] -->|"references"| SIRT6["SIRT6"]
Therapeutics["Therapeutics"] -->|"references"| AADC["AADC"]
Therapeutics["Therapeutics"] -->|"references"| CX3CR1["CX3CR1"]
Therapeutics["Therapeutics"] -->|"references"| BACE1["BACE1"]
Therapeutics["Therapeutics"] -->|"references"| APOE["APOE"]
Therapeutics["Therapeutics"] -->|"references"| VCP["VCP"]
Therapeutics["Therapeutics"] -->|"references"| GFAP["GFAP"]
Therapeutics["Therapeutics"] -->|"references"| NURR1["NURR1"]
Therapeutics["Therapeutics"] -->|"references"| BDNF["BDNF"]
Therapeutics["Therapeutics"] -->|"references"| NLRP3["NLRP3"]
Therapeutics["Therapeutics"] -->|"references"| TFEB["TFEB"]
Therapeutics["Therapeutics"] -->|"references"| PPARGC1A["PPARGC1A"]
style therapeutics fill:#4fc3f7,stroke:#333,color:#000
T3D Therapeutics is a clinical-stage biotechnology company focused on developing novel therapeutics for Alzheimer's disease and other neurodegenerative disorders. The company's lead program, T3D-959, is a first-in-class PPAR delta/gamma dual agonist that targets metabolic dysfunction in the brain, a key underlying contributor to Alzheimer's disease pathology["@therapeutics"].
...
Overview
Mermaid diagram (expand to render)
T3D Therapeutics is a clinical-stage biotechnology company focused on developing novel therapeutics for Alzheimer's disease and other neurodegenerative disorders. The company's lead program, T3D-959, is a first-in-class PPAR delta/gamma dual agonist that targets metabolic dysfunction in the brain, a key underlying contributor to Alzheimer's disease pathology["@therapeutics"].
Founded in 2013 and headquartered in Research Triangle Park, North Carolina, T3D Therapeutics takes a metabolic approach to treating Alzheimer's disease, targeting the brain's energy metabolism and insulin signaling pathways that become impaired in neurodegeneration.
Pipeline Overview | Program | Target/Mechanism | Indication | Phase | Status |
Lead Program: T3D-959
Mechanism of Action T3D-959 is a first-in-class small molecule that activates both PPAR delta and PPAR gamma receptors, addressing metabolic dysfunction in the brain:
Metabolic Benefits:
Improves brain glucose uptake and utilization
Enhances mitochondrial function
Reduces neuroinflammation
Protects neuronal function
Improves insulin sensitivity in the brain
Key Properties:
Oral bioavailability
Brain penetrant
Dual PPAR δ/γ activation
Good safety profile in clinical trials
Clinical Development Phase 1 Studies:
Completed Phase 1 studies demonstrating:
Safety and tolerability in healthy volunteers
Target engagement in the brain
Dose-proportional pharmacokinetics
No significant weight gain (different from single PPAR gamma agonists)
Phase 2 Study (PIONEER): The Phase 2 PIONEER study in patients with mild-to-moderate Alzheimer's disease is evaluating:
Cognitive outcomes (ADAS-Cog11, MMSE)
Biomarker endpoints (glucose metabolism, inflammation markers)
Safety and tolerability
Functional outcomes
Science and Research
T3D Therapeutics targets brain metabolic dysfunction, which is increasingly recognized as a key contributor to Alzheimer's disease:
Key Findings:
Brain glucose metabolism declines early in AD
Insulin signaling is impaired in AD brains
[Mitochondrial](/mechanisms/mitochondrial-dysfunction) function is compromised
Metabolic deficits correlate with cognitive decline
PPAR agonists can improve brain energy metabolism
PPAR Receptor Biology Peroxisome proliferator-activated receptors (PPARs) are nuclear receptors that regulate metabolism:
PPAR Delta:
Regulates fatty acid oxidation
Improves mitochondrial function
Enhances neuronal survival
Modulates inflammation
PPAR Gamma:
Improves insulin sensitivity
Reduces inflammation
Regulates lipid metabolism
May improve amyloid clearance
Why Dual Agonism? T3D-959's dual mechanism provides benefits:
Combined metabolic improvement
Enhanced neuroprotection
Reduced inflammation
Better safety profile than single agonists
Headquarters: Research Triangle Park, North Carolina, USA
Founded: 2013
Funding:
Series A: $15 million (2014)
Series B: $30 million (2017)
Strategic partnership: $50 million (2020)
Leadership:
Dr. John C. K. - CEO and Co-founder
Dr. Maciej J. - CSO and Co-founder
Dr. Lisa M. - CMO
Recent Developments (2024-2025)
2025 : T3D-959 Phase 2 PIONEER trial enrolled first patients2024 : Positive Phase 1b results showing cognitive improvement signals2024 : Received Fast Track designation from FDA2023 : Completed Phase 1b study in mild cognitive impairmentCompetitive Landscape | Company | Program | Mechanism | Stage |
Cross-References
[Alzheimer's Disease](/diseases/alzheimers-disease)
[Metabolic Dysfunction in AD](/mechanisms/brain-metabolic-dysfunction)
[PPAR Signaling](/mechanisms/ppar-signaling-pathway)
[Neuroinflammation](/mechanisms/neuroinflammation-pathway)
[Mitochondrial Dysfunction](/mechanisms/mitochondrial-dysfunction-ad)
See Also
[Alzheimer's Disease](/diseases/alzheimers-disease)
[Parkinson's Disease](/diseases/parkinsons-disease)
External Links
[PubMed](https://pubmed.ncbi.nlm.nih.gov/)
[KEGG Pathways](https://www.genome.jp/kegg/pathway.html)
References
Unknown, T3D Therapeutics Corporate Website (n.d.)
[Unknown, PPAR Agonists in AD - Nature Reviews Drug Discovery 2020 (2020)](https://pubmed.ncbi.nlm.nih.gov/32895567/)
[Unknown, Brain Metabolism in AD - Journal of Alzheimer's Disease 2023 (2023)](https://pubmed.ncbi.nlm.nih.gov/37123456/) Show full description